Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Abecma is the first CAR T approved for use in earlier lines of therapy for patients with relapsed or refractory multiple myeloma in Japan – BMS

Written by | 11 Dec 2023

Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a… read more.

EU approves Abecma for multiple myeloma – BMS

Written by | 23 Aug 2021

Bristol Myers Squibb announced that the European Commission has granted Conditional Marketing Authorization for Abecma (idecabtagene vicleucel; ide-cel), a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)… read more.

EMA gives green light for 8 new medicines

Written by | 17 Jul 2021

The European Medicine Agency’s key decision-making committee on human medicines (CHMP), has recommended eight medicines for approval at its June meeting.  The Committee recommended granting a conditional marketing authorisation for Abecma… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.